Dihydroberberine vs. berberine: how do absorption, effects and safety differ?

Is dihydroberberine absorbed better than berberine, and does it therefore lower blood sugar more? A small pilot study offers a hint that absorption is better: after lower doses of dihydroberberine, berberine levels in the blood were higher. That does not establish a correspondingly greater benefit for blood sugar control. Conventional berberine has been tested in far more clinical studies. Both substances can interact with medicines, and neither replaces prescribed treatment for diabetes or obesity.

How dihydroberberine differs from conventional berberine

The advantage of dihydroberberine (DHB) that is visible so far lies mainly in its pharmacokinetics, meaning how the body absorbs, distributes and breaks down a substance. A change in structure makes DHB more fat-soluble and helps it cross the gut wall. Whether it acts differently or better once it reaches its target is a separate question. No such superior pharmacodynamic effect has been shown; the two compounds share their key pharmacological properties.

Dihydroberberine is a reduced metabolite of berberine: a breakdown product formed by a chemical reduction reaction. It belongs to the family of protoberberine alkaloids. In the human gut, bacteria use the enzyme nitroreductase to turn berberine into this more readily absorbed form. DHB is also manufactured directly as a dietary supplement. Cheng et al., 2022

That is why research on berberine helps put DHB in context. Dozens of randomized controlled trials (RCTs) have looked at berberine’s metabolic effects. In such trials, participants are assigned at random to a treatment or a comparison group. Several meta-analyses pool the results of individual trials. For DHB, each claim has to be checked: was a difference from berberine actually studied, or is it only inferred from the altered structure and absorption?

Chemistry and structure

Berberine carries a quaternary ammonium group. Its positively charged nitrogen atom makes the molecule highly polar, which makes it harder to absorb through the gut wall. After reduction, the nitrogen in dihydroberberine is a tertiary amine. This makes the molecule more lipophilic, or fat-soluble. Fat-soluble compounds pass through biological membranes more easily than highly polar ones. This is the basis for the assumption of higher bioavailability: a larger share of the dose taken might reach the bloodstream.

In rats, giving dihydroberberine through the skin produced higher berberine levels in the body than giving it by mouth. Closely related reduced compounds have also been studied preclinically, that is, before any use in humans. One of them is 8,8-dimethyldihydroberberine, which showed better bioavailability and efficacy after oral dosing in mouse models of obesity and diabetes. These results provided early mechanistic clues for the group of reduced berberine compounds. They do not demonstrate a corresponding clinical effect in humans. Commercial DHB is mostly sold as a racemic mixture, a blend of two spatially different forms of the molecule known as stereoisomers. Buchanan et al., 2018, Cheng et al., 2010

Origins and history of use

Berberine has been used in traditional Chinese medicine for centuries. It occurs in Berberis species such as barberry, in Coptis chinensis, Hydrastis canadensis and related plants. These plants were used for digestive complaints and metabolic disorders long before their pharmacological properties were described.

Dihydroberberine as a supplement in its own right, by contrast, is a modern development. In the gut it forms naturally as an intermediate in berberine metabolism: bacteria that produce nitroreductase convert berberine into DHB, which makes it easier to absorb. The market for DHB products is smaller than the one for conventional berberine, and the supply chains are less established. Clinical studies on DHB are also much rarer. Cheng et al., 2022

Why dihydroberberine is absorbed differently, and what happens next

The claimed advantage of DHB concerns mainly how much of it reaches the bloodstream. There is no evidence that it works through a fundamentally different metabolic pathway than berberine.

After absorption, the body converts DHB back into berberine. The effects described from that point on involve the same AMPK signaling pathway as conventional berberine. The marketing label “Ozempic-like” does not describe this mechanism accurately. Berberine and DHB do not replace prescribed medicines such as semaglutide or tirzepatide for treating obesity or type 2 diabetes. Semaglutide is a GLP-1 receptor agonist, which means it binds to the GLP-1 receptor and activates it. Tirzepatide acts on both GIP and GLP-1 receptors.

Mechanism of action

A mechanistic study from 2006 showed in animal and cell models that berberine activates AMP-activated protein kinase (AMPK), an enzyme that helps the cell sense its energy status. Berberine also boosted the movement of the glucose transporter GLUT4 to the cell surface. In these models, glucose tolerance and insulin sensitivity improved. Through AMPK, muscle cells can take up more glucose from the blood without needing insulin directly. The study therefore describes a metabolic mechanism inside the cell. Lee et al., 2006

GLP-1 receptor agonists bind to the GLP-1 receptor. They promote insulin release, slow stomach emptying and influence appetite regulation in the brain. No comparable effect has been shown for berberine or DHB. Berberine and metformin, on the other hand, can both activate AMPK and affect some of the same metabolic pathways. That does not mean they are equally effective in the clinic, or that they are interchangeable. The phrase “nature’s Ozempic” mixes up different pharmacological mechanisms. Wang et al., 2018

Pharmacokinetics: absorption, half-life and metabolism

The oral bioavailability of conventional berberine is low, estimated at about 1%. Its observed metabolic effects might arise to a considerable degree through gut microbes. If so, they would not depend solely on how much reaches the blood. Changes in the gut microbiota, the community of microorganisms living in the gut, are considered a possible part of its antidiabetic effect. That could explain why clinical trials find measurable effects on blood sugar despite poor absorption into the bloodstream. This apparent contradiction is called the “low bioavailability paradox.” Han et al., 2011

DHB is already more fat-soluble when it is absorbed. In a randomized, double-blind crossover pilot study in healthy men, 100 mg and 200 mg of DHB led to significantly higher berberine concentrations in plasma (the liquid part of the blood) than 500 mg of conventional berberine. In a crossover design, participants receive the different treatments one after another. The result points to a pharmacokinetic difference. Preclinical data from a rat study fit with this: there, DHB applied through the skin produced higher berberine levels than berberine given by mouth. That comparison, however, has not been repeated directly in humans. Overall, there are few data on DHB pharmacokinetics in humans. Also poorly described are the effect of meals on absorption and the DHB-specific half-life, the time it takes for the concentration to fall by half. Moon et al., 2021, Buchanan et al., 2018

What research on dihydroberberine shows

The clinical data support a limited advantage: DHB can produce higher plasma berberine levels at a lower oral dose. Whether that improves blood sugar control or insulin sensitivity more than conventional berberine cannot be said yet.

Claims about DHB raise four separate questions. How well is it absorbed? Does it achieve the same or stronger blood sugar effects at a lower dose? What is known in general about its effect on blood sugar regulation? And is there any basis for marketing it as having a GLP-1-like effect or as “Nature’s Ozempic”?

The evidence labels below come from the English source article. How much weight each claim can bear depends mainly on which substance, which participants and which outcomes were actually studied.

Higher oral bioavailability of dihydroberberine: rated as moderate evidence

The main evidence is a crossover pilot study from 2021. In healthy men, 100 to 200 mg of DHB led to higher plasma berberine concentrations than 500 mg of conventional berberine. The underlying conversion step in the gut has been described: bacterial nitroreductases convert berberine into the more readily absorbed dihydroberberine. Moon et al., 2021, Cheng et al., 2022

The small sample limits what the study can tell us. The results come from a pilot study, so there is no large pharmacokinetic investigation yet. DHB has had much less research of this kind than berberine. The pilot data support the plausible assumption that DHB reaches the bloodstream more efficiently. They do not yet show whether this also improves clinical outcomes.

Same or stronger blood sugar effects at lower DHB doses: limited evidence

The 2021 bioavailability finding supports the hypothesis that a smaller dose of DHB could lead to similar berberine exposure, meaning a comparable amount of active compound in the body. For blood sugar effects in people with diabetes or prediabetes, however, the evidence from a DHB-specific randomized trial is missing.

Several results are reported for conventional berberine. A meta-analysis of 16 RCTs found significant reductions in HbA1c, fasting plasma glucose and glucose after a meal. Another meta-analysis is cited with a mean HbA1c difference of −0.73; no clear unit is given for this figure. An overarching meta-analysis describes improvements in FPG, HbA1c, HOMA-IR and inflammatory markers in metabolic disorders. FPG stands for fasting plasma glucose, and HbA1c reflects longer-term blood sugar exposure. HOMA-IR is an index of insulin resistance calculated from fasting insulin and fasting glucose. Meta-analysis on metabolic profiles, Meta-analysis on glucose lowering, Umbrella meta-analysis

These results do not automatically apply to DHB. Higher bioavailability might allow a lower dose to reach a similar concentration in the body. There is no evidence that better clinical outcomes follow from that.

Effect on blood sugar regulation: rated as strong, but not shown for every form of berberine

Of the claims considered here, the effect of conventional berberine on blood sugar regulation is the best supported. A meta-analysis published in Frontiers in Pharmacology in 2022 is credited with significant reductions in HbA1c, fasting plasma glucose and glucose 2 hours after a meal across 16 RCTs. A second meta-analysis is cited with a mean HbA1c difference of −0.73 in people with type 2 diabetes. The matching of study description, year and reference is partly unclear here. Linked meta-analysis 1, linked meta-analysis 2

A further umbrella meta-analysis, which pools the results of several meta-analyses, is described as showing improvements in FPG, HbA1c, HOMA-IR and the inflammatory markers IL-6, TNF-alpha and CRP in adults with metabolic disorders. Two different PubMed addresses are given for this work, though, and which one belongs to it is unclear. A 2025 meta-analysis of placebo-controlled trials also reports significant reductions in triglycerides (TG), fasting plasma glucose and waist circumference. The trials differ considerably from one another, and the quality of commercial products varies too. Linked umbrella meta-analysis, Liu et al., 2025

The claim that berberine supports blood sugar regulation “in any form” goes beyond the direct data. Whether DHB achieves the same clinical effects at a different dose needs to be studied separately. Better absorption alone does not answer that question.

“Nature’s Ozempic” and a GLP-1-like effect: anecdotal

The label “Nature’s Ozempic” does not fit the mechanism described. Berberine and DHB are linked to AMPK activation and increased movement of GLUT4 to the cell surface. These processes take place inside the cell. GLP-1 receptor agonists, by contrast, bind to the GLP-1 receptor. They promote insulin release from the pancreas, slow stomach emptying and influence appetite in the brain. The clinical effect sizes cannot be considered equivalent either. “Nature’s Ozempic” is a marketing phrase, not a pharmacological description. Berberine does not replace prescribed GLP-1 therapy for obesity or type 2 diabetes. Lee et al., 2006

For DHB, too, neither an action as a GLP-1 receptor agonist nor suitability as a substitute for prescribed GLP-1 receptor agonists has been shown. Head-to-head studies at equal systemic exposure, meaning a comparable amount of active compound in the body, have not so far shown fundamentally better clinical outcomes than berberine. DHB is not approved as a drug by the US FDA for any condition.

Three forms of berberine compared

Conventional berberine, DHB and berberine phytosome differ in how they are absorbed. Depending on the formulation, the differences in bioavailability can reach an order of magnitude, roughly tenfold.

This affects how much active compound reaches the bloodstream. When comparing products, it therefore matters whether the product on offer and its dose match the preparations that were studied. Higher absorption alone does not tell us which form works better clinically.

• Conventional berberine HCl is often standardized to about 97% berberine hydrochloride and usually sold in 500 mg capsules. Studies and common regimens use 2 to 3 doses a day. Oral bioavailability is roughly 1%. Gut microbes are involved in a large part of its metabolism, and bacterial nitroreductases convert some of the berberine into DHB along the way. A Certificate of Analysis (COA) should show independent heavy metal testing. Documented standardization and a reliable supplier also help in judging product quality. Cheng et al., 2022
• Berberine phytosome is a complex of berberine and phosphatidylcholine. A 550 mg amount of phytosome typically provides about 100 to 110 mg of berberine equivalents. Pharmacokinetic studies suggest that at a comparable dose, more berberine reaches the plasma than with conventional berberine. The COA should document the phytosome form.
• Dihydroberberine is the reduced metabolite of berberine and is typically sold at 100 to 200 mg per capsule. In pharmacokinetic pilot studies, lower doses led to higher plasma concentrations than conventional berberine. Human data are limited, and the supply chains are less established. In this smaller market, independent testing programs cover fewer individual products, so the Certificate of Analysis deserves particular attention. Moon et al., 2021

These amounts describe products and studies. They are not a personal dosing recommendation.

Independent testing programs such as USP, NSF International and ConsumerLab check, depending on the program, whether a product meets its label claims, whether it contains contaminants and how it disintegrates. For plant-derived berberine, heavy metal contamination, especially with lead and cadmium, is described as a quality problem. A meaningful COA should therefore include a heavy metal analysis by ICP-MS. This method, inductively coupled plasma mass spectrometry, detects metals. Testing only for microbial limits does not cover this risk.

What standardization details are needed depends on the form. For berberine HCl, the alkaloid content should be confirmed by high-performance liquid chromatography (HPLC). For phytosomes, both the phosphatidylcholine content and the berberine equivalents belong on the certificate. For DHB, identity confirmation by nuclear magnetic resonance spectroscopy (NMR) or HPLC is relevant. Because the supplier base is smaller, adulteration with or substitution by conventional berberine is considered a plausible quality risk. Appropriate testing should catch such deviations.

Regulatory status as of May 2026

Neither berberine nor DHB is approved as a drug by the FDA in the United States. Both are marketed there as dietary supplements.

The information for May 2026 places both substances in the US under the Dietary Supplement Health and Education Act (DSHEA). Neither has FDA drug approval for any specific indication. This information does not name any restriction on the whole product category based on its New Dietary Ingredient (NDI) filing history. This classification concerns the US market; it cannot be carried over to the legal status in Germany or the EU.

The FDA has repeatedly sent warning letters over berberine products that made explicit promises to treat diseases, such as diabetes or high cholesterol. Under DSHEA, such statements cross the line of permitted structure or function claims and count as drug claims. For DHB, no specific pattern of such warning letters is described as of May 2026. The market is small, however, and regulatory attention may grow as it expands.

As of the same date, berberine and DHB are not on the World Anti-Doping Agency (WADA) Prohibited List. No substance-specific restrictions under sports rules are given. Under DSHEA, statements such as “supports healthy blood sugar levels already within the normal range” may be permitted with the required disclaimers. That does not grant permission to advertise treatment of diabetes, prediabetes or any other disease. The regulatory and sports-rule information applies to the date stated.

Safety, side effects and interactions of berberine

Berberine can inhibit CYP3A4 and CYP2D6, two enzymes that break down drugs. This can raise plasma levels of medicines cleared through these pathways, including ciclosporin, certain statins and some antiarrhythmics. This risk also applies to DHB, because the body converts it into berberine. How strong such interactions are with DHB, however, has been studied less. With drugs that have a narrow therapeutic index, effective and harmful doses lie close together. In that case, a conversation with the prescribing clinician is necessary before taking berberine or DHB.

Safety data for conventional berberine come from dozens of randomized trials. DHB-specific data are much scarcer. Statements about how well DHB is tolerated rest mostly on berberine data and on one assumption: lower oral doses might be easier on the digestive tract, even when a similar amount of active compound reaches the bloodstream. This assumption is plausible but has not been confirmed by large studies.

Reported side effects

The side effects reported most often in berberine trials are digestive complaints. A randomized pilot study compared berberine with metformin in newly diagnosed type 2 diabetes. About 34% of the people treated with berberine had temporary gastrointestinal side effects, mainly constipation, abdominal discomfort and temporary diarrhea. The 34% figure applies to that study. It does not describe the general rate among everyone who takes berberine or DHB. Yin et al., 2008

A review of its effects in the gastrointestinal tract describes antidiarrheal and anti-inflammatory actions, and also mostly mild digestive complaints as a tolerability problem. A meta-analysis of 12 RCTs found moderate reductions in body weight and CRP, with no significant changes in liver enzymes. In the studies and case reports cited, digestive complaints at usual supplement doses were more prominent than liver damage or serious systemic side effects. That does not rule out rare serious risks, though. Chen et al., 2014, Asbaghi et al., 2020

Drug interactions

The severity levels below follow the ratings in the English source article. How relevant an interaction is in a given case also depends on the particular medicine.

• CYP3A4 substrates, including some statins, certain immunosuppressants and some calcium channel blockers: rated as a moderate interaction. If berberine inhibits CYP3A4, plasma levels of medicines taken at the same time can rise, and dose-dependent side effects can increase. According to the reference list, however, the PubMed reference cited for this belongs to a paper on the gut microbiota and does not clearly support this specific claim.
• Insulin and sulfonylureas: rated as a moderate interaction. The blood-sugar-lowering effects can add up. Without medical supervision, blood sugar can fall below the target range.
• Anticoagulants, especially warfarin: rated as a moderate interaction. An interaction signal with these blood thinners has been described for berberine. A medical review is required. With warfarin, this includes monitoring the INR, the value that reflects how strongly clotting is suppressed.
• Antibiotics: rated as minor to moderate. Berberine has antimicrobial properties and can change the composition of the gut microbiota. The treating clinician should therefore know if both are being taken.
• Blood pressure medicines: rated as minor to moderate. Their effect and a possible blood-pressure-lowering effect of berberine could add up. This should be discussed especially when several blood pressure drugs are prescribed at once.

Pregnancy, breastfeeding, and liver and kidney function

Berberine and dihydroberberine should not be taken during pregnancy or breastfeeding. Berberine can displace bilirubin from its binding sites on the transport protein albumin and so raise the share of free bilirubin in newborns. Controlled human safety data at supplement doses are lacking.

For breastfeeding, it is also not sufficiently clear how much berberine passes into breast milk.

At usual doses, berberine showed no significant overall effect on liver enzymes in the meta-analysis mentioned above. Even so, people with known liver disease should have the liver enzymes ALT and AST measured by a doctor as baseline values before taking it. For people with reduced kidney function, there are only limited controlled human data; use should be under medical supervision. As of May 2026, no DHB-specific data have been described for these groups. Asbaghi et al., 2020

Who should avoid dihydroberberine and berberine

During pregnancy and breastfeeding, the recommendation is to avoid both substances. In the other situations listed below, taking them should only be considered after a medical assessment.

The reasons are specific interaction signals or missing safety data. Not every point is a formal contraindication; some call for an individual judgment:

• Pregnancy or breastfeeding: Controlled safety data at supplement doses are lacking. There is also a described risk of raised bilirubin levels in newborns.
• Treatment with insulin or sulfonylureas without medical supervision: Additional blood sugar lowering can go as far as hypoglycemia.
• Taking warfarin or other blood thinners: A medical review is required, including INR checks for warfarin.
• Prescribed CYP3A4 substrates, such as certain statins, immunosuppressants or calcium channel blockers: There is a risk of interactions.
• Known liver disease without baseline ALT and AST values: These values should be measured by a doctor before taking it is considered.
• Children: Doses and safety as a supplement have not been adequately studied in children.

For this assessment, the clinician needs the complete medication list and the relevant lab results.

DHB, berberine and berberine phytosome side by side

Which form might be suitable depends on the outcome you are after and the matching body of research. Digestive tolerance, cost and product quality can also play a role.

A higher blood concentration is not enough to decide on. The three forms also differ in how well their clinical effects have been studied.

Feature	Conventional berberine	Dihydroberberine	Berberine phytosome
Origin and chemistry	Protoberberine alkaloid from Berberis, Coptis or Hydrastis	Reduced metabolite of berberine; manufactured or formed by gut bacteria	Berberine bound to a phosphatidylcholine carrier
Bioavailability	About 1% orally	Higher than conventional berberine in pharmacokinetic pilot data. Moon et al., 2021	Reported plasma exposure about 5 to 10 times higher than a comparable dose of conventional berberine
Strongest evidence	More extensive RCT data and several meta-analyses on HbA1c, FPG and blood lipids; cited are a 2022 meta-analysis of 16 RCTs, a 2021 HbA1c meta-analysis and a 2024 umbrella meta-analysis. The references are partly not clearly matched. Reference 1, Reference 2, Reference 3	2021 pharmacokinetic pilot study; no large RCTs with clinical endpoints cited	Pharmacokinetic data and smaller clinical studies; the amount of data is placed between the other two forms
Amounts studied	500 mg, 2 to 3 times a day	100 to 200 mg per capsule in pharmacokinetic studies	About 550 mg of phytosome, corresponding to roughly 100 mg of berberine
Key safety considerations	Interaction potential via CYP3A4, additional blood sugar lowering and a signal for interactions with blood thinners	A comparable range of risks should be assumed; higher systemic exposure could amplify effects and interactions	A comparable range of risks should be assumed; higher systemic exposure could amplify effects and interactions
Relative cost	$	$$ to $$$	$$ to $$$
Regulatory status	Described as sold in the US under DSHEA as of May 2026; no FDA drug approval	Described as sold in the US under DSHEA as of May 2026; no FDA drug approval and no specific pattern of FDA warning letters described	Described as sold in the US under DSHEA as of May 2026; no FDA drug approval

The largest body of RCT and meta-analysis literature on clinical endpoints exists for conventional berberine. If digestive complaints or the number of capsules are the main concern at usual 500 mg doses, better-absorbed forms might allow similar systemic exposure at a lower oral dose. That does not yet prove they are better tolerated. More human pharmacokinetic data are described for the phytosome form than for DHB. With DHB, the supply chains are less established and the data on clinical outcomes are thinner.

To judge longer-term changes in blood sugar, HbA1c is used. A repeat measurement after 8 to 12 weeks, compared against a documented baseline value, is suggested. Such a trend can show a change, but on its own it does not prove the product caused it.

Which lab values can capture changes while taking berberine

AMPK activation, GLUT4 movement and changes in fat metabolism are processes whose possible effects partly show up in blood values. Baseline values help in judging changes while taking a supplement. A before-and-after comparison cannot, however, rule out that natural fluctuations, other treatments or lifestyle changes are responsible.

• HbA1c reflects average blood sugar exposure over roughly 3 months. It works as a longer-term endpoint for judging changes in glucose regulation. For follow-up, a repeat measurement no earlier than 12 weeks is suggested here. Earlier measurements do not yet cover the full period since starting.
• Fasting insulin can be used together with fasting glucose to calculate HOMA-IR, an established index of insulin resistance. Changes in insulin sensitivity may show up there sooner than in HbA1c, that is, before the 3-month HbA1c window has passed.
• Fasting glucose is a direct measure of glucose regulation. Meta-analyses of berberine repeatedly report reductions in fasting plasma glucose. This is one of the more frequently observed findings in berberine research. Meta-analysis on glucose lowering
• LDL-C is the cholesterol content of LDL particles. A meta-analysis of 16 RCTs found significant reductions in total and LDL cholesterol with berberine. LDL-C is part of the standard lipid panel and, together with blood sugar values, can help put the trend in context. Ju et al., 2018
• ApoB, apolipoprotein B, reflects the number of atherogenic particles, those that promote atherosclerosis. These include LDL, VLDL, IDL and Lp(a). The value therefore describes something different from the amount of cholesterol in LDL alone. It can give a more precise picture of cardiovascular risk driven by blood lipids and add information when judging possible lipid effects of berberine.
• ALT and AST are liver enzymes that can point to damage to liver cells. In the meta-analysis cited, berberine did not significantly change liver enzymes at usual doses. With known liver disease or already raised transaminases (the group ALT and AST belong to), a medical assessment of baseline values before taking it is important. Otherwise, too, existing baseline values can make a later comparison easier. Asbaghi et al., 2020

Without HbA1c, fasting glucose and a lipid panel measured beforehand, later changes are hard to interpret. An unusual value can move closer to the normal range on a repeat test even without effective treatment. This statistical effect is called regression to the mean. Baseline values help in judging such trends but do not rule them out. Which tests make sense depends on the clinical question, so a comprehensive test package is not needed across the board.

When DHB is not the right answer

Symptoms or abnormal lab values should be checked medically before deciding on a supplement.

This applies, for example, to unexplained tiredness, frequent urination, blurred vision or marked weight gain, and to raised fasting glucose or HbA1c. Prediabetes, type 2 diabetes, metabolic syndrome and familial hypercholesterolemia have diagnostic criteria and established treatment pathways. A dietary supplement does not replace them. The first step is a metabolic assessment by a primary care doctor. If prediabetes or metabolic syndrome is suspected, an endocrinologist may be brought in depending on the findings. Whether one form of berberine is absorbed better does nothing to clarify the diagnosis.

Especially in a large and comparatively loosely regulated supplement market, reliable baseline results help in making sense of possible changes. Whether berberine in any form suits a particular situation has to be judged separately.

Frequently asked questions

What is the difference between dihydroberberine and berberine?

Dihydroberberine is the reduced metabolite of berberine. In a small pilot study, lower doses of it led to higher plasma berberine levels than conventional berberine. Both compounds are linked to the same AMPK signaling pathway. The difference that has been studied therefore concerns mainly bioavailability. Correspondingly better clinical effectiveness of DHB has not been shown. Moon et al., 2021, Lee et al., 2006

Does dihydroberberine work better than berberine?

That has not been shown so far. The DHB data come mainly from small pharmacokinetic pilot studies in healthy men. Conventional berberine has far more RCT data on blood sugar regulation, and they point to possible blood-sugar-lowering effects. A reliable head-to-head comparison would need larger DHB studies that look at the relevant clinical endpoints, and those are missing. Moon et al., 2021, Meta-analysis on glucose lowering

What doses of dihydroberberine have been used in studies?

Pharmacokinetic comparison studies compared 100 to 200 mg of dihydroberberine with 500 mg of berberine. RCTs on conventional berberine often used about 500 mg 2 to 3 times a day. These figures describe doses that were studied and are not an individual dosing recommendation. Moon et al., 2021

What are the side effects of dihydroberberine?

Specific safety data for DHB are limited. Berberine studies mainly report digestive complaints such as constipation, mild abdominal discomfort and temporary diarrhea. In one pilot study, such temporary complaints occurred in about 34% of people treated with berberine. Similar complaints are possible with DHB, but the rate from the berberine study cannot be transferred to DHB. Yin et al., 2008, Chen et al., 2014

Is dihydroberberine FDA-approved?

Dihydroberberine is not an FDA-approved drug. According to the information for May 2026, berberine and DHB are sold in the US as dietary supplements under the Dietary Supplement Health and Education Act (DSHEA). Neither has an approved New Drug Application, the application required for drug approval. No notable NDI filing or warning letter history specific to DHB is described. None of this confirms effectiveness, safety or legal status in other countries.

Is dihydroberberine better than berberine phytosome?

No clear superiority has been shown. Berberine phytosome is described as giving roughly 5 to 10 times higher plasma exposure than conventional berberine. For DHB, mainly pharmacokinetic pilot data are available. Both forms target the same basic AMPK-linked metabolic mechanisms. They differ in cost, supply chains and quality control. Which form works better clinically cannot be inferred from absorption alone. Moon et al., 2021

Can dihydroberberine interact with medicines?

Yes. Interactions with CYP3A4 substrates, such as certain statins and immunosuppressants, deserve particular attention. A pharmacokinetic interaction between berberine and a statin has been described in an animal model. How clinically relevant it is in humans has not been fully settled. Stronger blood sugar lowering together with insulin or sulfonylureas and interactions with blood thinners are also possible. A medical review is needed before combining them. Review on cytochrome P450, Wu et al., 2023

Which blood tests make sense before starting dihydroberberine?

To assess metabolism and the liver, HbA1c, fasting insulin, fasting glucose, LDL-C, ApoB, and ALT and AST are options. Which values are needed depends on existing conditions, medicines and the specific question. Follow-up measurements can show changes, but on their own they do not prove that DHB caused them.

As a point of comparison, a repeat measurement after 8 to 12 weeks at the same lab and under similar morning conditions is suggested. For HbA1c, the corresponding main section gives at least 12 weeks instead. The timing given is not fully consistent. The follow-up time point should fit the value being checked and the medical reason for testing.

References

1. Cheng H, Liu J, Tan Y, Feng W, Peng C (2022). Interactions between gut microbiota and berberine, a necessary procedure to understand the mechanisms of berberine. Journal of pharmaceutical analysis, 12(4), 541-555. https://doi.org/10.1016/j.jpha.2021.10.003

2. Buchanan B, Meng Q, Poulin MM, Zuccolo J, Azike CG, Gabriele J, Baranowski DC (2018). Comparative pharmacokinetics and safety assessment of transdermal berberine and dihydroberberine. PloS one, 13(3), e0194979. https://doi.org/10.1371/journal.pone.0194979

3. Cheng Z, Chen AF, Wu F, Sheng L, Zhang HK, Gu M, Li YY, Zhang LN, Hu LH, Li JY, Li J (2010). 8,8-Dimethyldihydroberberine with improved bioavailability and oral efficacy on obese and diabetic mouse models. Bioorganic & medicinal chemistry, 18(16), 5915-24. https://doi.org/10.1016/j.bmc.2010.06.085

4. Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, Ye JM, Lee CH, Oh WK, Kim CT, Hohnen-Behrens C, Gosby A, Kraegen EW, James DE, Kim JB (2006). Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes, 55(8), 2256-64. https://doi.org/10.2337/db06-0006

5. Wang H, Zhu C, Ying Y, Luo L, Huang D, Luo Z (2018). Metformin and berberine, two versatile drugs in treatment of common metabolic diseases. Oncotarget, 9(11), 10135-10146. https://doi.org/10.18632/oncotarget.20807

6. Han J, Lin H, Huang W (2011). Modulating gut microbiota as an anti-diabetic mechanism of berberine. Medical science monitor : international journal of experimental and clinical research, 17(7), RA164-7. https://doi.org/10.12659/msm.881842

7. Moon JM, Ratliff KM, Hagele AM, Stecker RA, Mumford PW, Kerksick CM (2021). Absorption Kinetics of Berberine and Dihydroberberine and Their Impact on Glycemia: A Randomized, Controlled, Crossover Pilot Trial. Nutrients, 14(1). https://doi.org/10.3390/nu14010124

8. Xie W, Su F, Wang G, Peng Z, Xu Y, Zhang Y, Xu N, Hou K, Hu Z, Chen Y, Chen R (2022). Glucose-lowering effect of berberine on type 2 diabetes: A systematic review and meta-analysis. Frontiers in pharmacology, 13, 1015045. https://doi.org/10.3389/fphar.2022.1015045

9. Guo J, Chen H, Zhang X, Lou W, Zhang P, Qiu Y, Zhang C, Wang Y, Liu WJ (2021). The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Oxidative medicine and cellular longevity, 2021, 2074610. https://doi.org/10.1155/2021/2074610

10. Nazari A, Ghotbabadi ZR, Kazemi KS, Metghalchi Y, Tavakoli R, Rahimabadi RZ, Ghaheri M (2024). The effect ofberberine supplementation on glycemic control and inflammatory biomarkers in metabolic disorders: An umbrella meta-analysis of randomized controlled trials. Clinical Therapeutics, 46(2), e64-e72. https://doi.org/10.1016/j.clinthera.2023.10.019

11. Liu D, Zhao H, Zhang Y, Hu J, Xu H (2025). Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials. Frontiers in pharmacology, 16, 1572197. https://doi.org/10.3389/fphar.2025.1572197

12. Yin J, Xing H, Ye J (2008). Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism: clinical and experimental, 57(5), 712-7. https://doi.org/10.1016/j.metabol.2008.01.013

13. Chen C, Yu Z, Li Y, Fichna J, Storr M (2014). Effects of berberine in the gastrointestinal tract - a review of actions and therapeutic implications. The American journal of Chinese medicine, 42(5), 1053-70. https://doi.org/10.1142/S0192415X14500669

14. Asbaghi O, Ghanbari N, Shekari M, Reiner, Ž., Amirani E, Hallajzadeh J, Mirsafaei L, Asemi Z (2020). The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials. Clinical nutrition ESPEN, 38, 43-49. https://doi.org/10.1016/j.clnesp.2020.04.010

15. Ju J, Li J, Lin Q, Xu H (2018). Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials. Phytomedicine : international journal of phytotherapy and phytopharmacology, 50, 25-34. https://doi.org/10.1016/j.phymed.2018.09.212

16. Bathaei P, Imenshahidi M, Hosseinzadeh H (2025). Effects of Berberis vulgaris, and its active constituent berberine on cytochrome P450: a review. Naunyn-Schmiedeberg’s archives of pharmacology, 398(1), 179-202. https://doi.org/10.1007/s00210-024-03326-x

17. Wu F, Cui M, Wang S, Yu C, Yin W, Li J, Yan X (2023). Effect of berberine on pharmacokinetics and pharmacodynamics of atorvastatin in hyperlipidemia rats. Xenobiotica; the fate of foreign compounds in biological systems, 53(12), 644-652. https://doi.org/10.1080/00498254.2023.2290648